20-F: EDAP TMS S.A. Files 20-F Report: Focus on HIFU Technology and U.S. Expansion

Sentiment:

Annual Report 27 March 2025 4:31 PM

EDAP TMS S.A.'s 20-F filing highlights the company's strategic shift towards HIFU technology and expansion in the U.S. market, while addressing financial challenges and risks.

Capital raiseThe company believes it has sufficient funds to support its operations for at least a period of twelve months from the date of issue of its consolidated financial statements.However, the company will need to raise substantial additional financing in order to meet its cash flow needs in the subsequent period and until it achieves profitability.Management is actively exploring various alternatives, including seeking additional funding through the debt and equity capital markets, cost-cutting measures, and restructuring opportunities.

Worse than expectedThe company's cash reserves decreased significantly, and it anticipates needing to raise additional financing.The company reported a net loss, indicating financial challenges.The company identified material weaknesses in its internal control over financial reporting.

Summary

EDAP TMS S.A. filed its 20-F report with the SEC on March 27, 2025, detailing its financial results for the fiscal year ended December 31, 2024.
The company is focusing on expanding its HIFU activities in the U.S. and worldwide to accelerate Focal One Robotic HIFU adoption.
EDAP TMS is shifting its strategy to focus on core proprietary HIFU activities and de-emphasizing non-HIFU distribution and ESWL business activities.
The company reported a consolidated net loss of 19.0 million in 2024, compared to a net loss of 21.2 million in 2023.
As of December 31, 2024, EDAP TMS had 29.8 million in cash and cash equivalents, a decrease of 13.6 million from December 31, 2023.
The company believes it has sufficient funds to support operations for at least twelve months but will need to raise additional financing to meet cash flow needs.
The HIFU division's total revenues increased by 15.7% from 20.6 million in 2023 to 23.8 million in 2024.
The ESWL division's total revenues decreased by 9.3% from 9.9 million in 2023 to 9.0 million in 2024.
The Distribution division's total revenues increased by 4.6% from 29.9 million in 2023 to 31.3 million in 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is growth in the HIFU division and strategic focus, the company faces financial challenges, including a net loss, decreased cash reserves, and the need for additional financing. The identification of material weaknesses in internal control also contributes to a neutral sentiment.

Positives

HIFU division revenue increased by 15.7%, indicating growth in the core business.
The company is actively exploring options to secure additional funding.
The HIFI study demonstrated that patients receiving HIFU treatments had better outcomes with respect to urinary continence and erectile function compared to patients receiving radical prostatectomy.
The 2025 final rule maintained the Urology Ambulatory Payment Classification (APC) 6 payment level for CPT 55880, translating to reimbursement to a hospital performing a HIFU procedure on a Medicare patient to $9,247 per procedure as a national average.

Negatives

The company reported a consolidated net loss of 19.0 million in 2024.
Cash reserves decreased by 13.6 million, leaving 29.8 million as of December 31, 2024.
The company anticipates needing to raise additional financing to sustain operations beyond the next twelve months.
The company is discontinuing system sales in its ESWL business, which will lead to a revenue decline in 2025 and subsequent periods.
Distribution agreements with third parties expired in December 2024 and were not renewed, which will have a material adverse effect on revenue.
Two material weaknesses were identified in internal control over financial reporting with respect to the U.S. subsidiary.

Risks

The company's ability to continue as a going concern is uncertain due to a history of losses and the need for additional financing.
The company's future revenue growth depends on the success of its HIFU technology.
The company's cash flow is highly dependent on cyclical demand for its products.
The company faces intense competition in the markets in which it operates.
The company is exposed to risks related to cybersecurity threats and incidents.
The company may experience revenue disruption due to its strategic shift to focus on HIFU activities.
The company has identified two material weaknesses in its internal control over financial reporting with respect to its U.S. subsidiary.

Future Outlook

EDAP TMS plans to increase investment levels in operational spending, including R&D, to strengthen its technological leadership in HIFU and explore applications beyond urology. The company also expects selling and marketing expenses to increase in connection with the acceleration of HIFU adoption in the U.S.

Management Comments

Management is actively exploring various alternatives, including seeking additional funding through the debt and equity capital markets, cost-cutting measures, and restructuring opportunities.
Management believes the measures described above will strengthen the Company's internal control over financial reporting.

Industry Context

The announcement reflects a broader trend in the medical device industry towards minimally invasive procedures and technological innovation. EDAP TMS is positioning itself to capitalize on the growing demand for non-invasive treatment options, particularly in the management of prostate cancer and other urological conditions.

Comparison to Industry Standards

The Focal One system competes with other HIFU systems like Sonablate (Sonablate Corporation) and Tulsa-Pro (Profound Medical), as well as traditional treatments like surgery and radiation.
The company's success depends on achieving favorable reimbursement rates from healthcare payers, similar to other medical device companies in the space.
The company's reliance on a single manufacturing site is a risk, similar to other companies with concentrated production facilities.
The company's strategic shift to focus on HIFU activities is a common strategy in the medical device industry, where companies often prioritize core competencies and high-growth areas.

Related Party Transactions

EDAP Technomed Co. Ltd. (Japan) contracted a loan requiring a personal guarantee from the representative director, president and CEO of the subsidiary, Mr. Jean-Franois Bachelard.
EDAP TMS S.A., as the parent company, counter-guaranteed this personal loan and agreed to indemnify Mr. Bachelard.

Stakeholder Impact

Shareholders may experience dilution if the company issues additional securities.
Employees may be affected by cost-cutting measures or restructuring opportunities.
Customers may benefit from the company's focus on HIFU technology and expansion in the U.S.

Next Steps

The company will continue to advance its research and development programs.
The company will continue to grow its operations.
The company will continue to explore opportunities for Intellectual Property protection.

Key Dates

Date	Description
December 3, 1979	EDAP TMS S.A. was incorporated.
July 31, 1997	Date of the original deposit agreement with The Bank of New York Mellon.
April 7, 2008	Date of the amended and restated deposit agreement with The Bank of New York Mellon.
September 2011	Enactment of the Leahy-Smith America Invents Act.
June 2013	Focal One received CE Marking.
November 2015	FDA 510(k) clearance for Ablatherm Integrated Imaging HIFU in the U.S.
October 2017	510(k) clearance for Ablatherm Fusion system.
June 7, 2018	FDA 510(k) clearance for Focal One system.
May 2018	General Data Protection Regulation (GDPR) took effect in the European Union.
September 30, 2019	Patients inclusion period closed on September 30, 2019 for the HIFI Study.
May 26, 2020	Initial transition time to meet new MDR requirements.
May 2020	Exclusive worldwide distribution agreement signed with Exact Imaging Inc.
May 26, 2021	Extended transition period to meet new MDR requirements.
January 1, 2021	New Category 1 CPT code for HIFU ablation of malignant prostate tissue became effective.
June 2021	Patient inclusion was completed in June 2021 for the FARP study.
September 2022	Phase II multi-center clinical study in France to further investigate the use of Focal One Robotic HIFU in the treatment of certain types of deep endometriosis situated in the low rectum was completed.
Late 2022	CMS published its final rules for the calendar year 2023 for ambulatory payment classification (APC) procedures and physician fee schedule, which established reimbursement rates that recognize both facility or hospital payment and physician professional service payments for HIFU procedures.
January 1, 2023	CMS final rule included a reimbursement level close to surgery, effective on January 1, 2023.
Early 2023	Data from the Phase II multi-center clinical study in France to further investigate the use of Focal One Robotic HIFU in the treatment of certain types of deep endometriosis situated in the low rectum have been analyzed and final results on safety and efficacy were presented in France at the Pari(s) Sant Femmes Gynecology Congress.
March 2023	The Study Coordinator presented the preliminary results of the HIFI Study at the European Association of Urology congress.
March 15, 2023	European regulation N2023/607 extended the validity of our Focal One CE certificate until December 31, 2028.
May 1, 2023	Mr. Ryan Rhodes was appointed as Chief Executive Officer of the Company.
Late 2023	A positive favorable opinion was issued to include HIFU as a procedure covered under the national universal health, Social Security system (Scurit Sociale).
December 2023	The Company renewed its agreement with Exact Imaging Inc.
March 2024	Focal One HIFU platform granted Breakthrough Device designation by the FDA for deep infiltrating endometriosis.
May 2024	Final results were presented at the 2024 Annual Meeting of the European Association of Urology in March as well as the American Urological Association in May.
June 28, 2024	Shareholders renewed and extended resolutions allowing the Board of Directors to issue new shares in an aggregate maximum amount of 15 million shares.
June 28, 2024	Shareholders also adopted resolutions allowing the Board of Directors to issue 2,000,000 new shares under the form of subscription options and 600,000 free shares.
June 30, 2025	The current distribution agreement with Exact Imaging Inc. will end.
July 1, 2025	A new agreement will be effective, providing (a) for the Companys non-U.S. subsidiaries to market and service the ExactVu directly to end-users and (b) for the Companys U.S. subsidiary to continue servicing and supporting customers in the United States based on the expiration dates of existing Service Agreements.
July 1, 2025	The new CPT Category 3 code to report the use of transrectal HIFU for the treatment of BPH will become effective.
December 2025	The Quanta distribution contract will be renewed with an expiration date of December 2025.
December 2025	The distribution contract with Laborie expires in December 2025.
December 31, 2028	Updated application date of European Medical Device Regulation (MDR).

Keywords

HIFU, EDAP TMS, Financial Results, Focal One, ESWL, Revenue, Net Loss, Expansion, U.S. Market, 20-F Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.